Skip to main content
Erschienen in:

01.12.2009 | Leitthema

Primäre und sekundäre Prävention sporadischer kolorektaler Karzinome

verfasst von: P. Thermann, Prof. Dr. T. Seufferlein

Erschienen in: Die Onkologie | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das kolorektale Karzinom (KRK) gehört zu den weltweit häufigsten Krebserkrankungen. Es entwickelt sich in den überwiegenden Fällen aus sporadischen Adenomen; bis zur Manifestation eines KRK können mehrere Jahre vergehen. Es bestehen effektive Präventionsmöglichkeiten zur Verringerung der Prävalenz und der Sterblichkeit des KRK. Dies beginnt bei der Lebensweise und wird durch zahlreiche zur Verfügung stehende Screeningverfahren ergänzt. Die Screeningkoloskopie stellt durch die Möglichkeit der Polypektomie das wahrscheinlich effektivste Verfahren zur Senkung der KRK-assoziierten Letalität dar – bei allerdings noch nicht ausreichender Akzeptanz in der Zielgruppe. Patienten mit erblicher Vorbelastung für ein KRK müssen besser identifiziert und in eigene Screeningprogramme integriert werden. Eine Chemoprävention kann derzeit aufgrund fehlender Evidenz oder einem ungünstigen Nebenwirkungsprofil nicht empfohlen werden.
Literatur
1.
Zurück zum Zitat Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488PubMedCrossRef Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488PubMedCrossRef
2.
Zurück zum Zitat Cho KR, Vogelstein B (1992) Genetic alterations in the adenoma–carcinoma sequence. Cancer 70:1727–1731PubMedCrossRef Cho KR, Vogelstein B (1992) Genetic alterations in the adenoma–carcinoma sequence. Cancer 70:1727–1731PubMedCrossRef
3.
Zurück zum Zitat Wong JJ, Hawkins NJ, Ward RL (2007) Colorectal cancer: a model for epigenetic tumorigenesis. Gut 56:140–148PubMedCrossRef Wong JJ, Hawkins NJ, Ward RL (2007) Colorectal cancer: a model for epigenetic tumorigenesis. Gut 56:140–148PubMedCrossRef
4.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
5.
Zurück zum Zitat Gunter MJ, Leitzmann MF (2006) Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 17:145–156PubMedCrossRef Gunter MJ, Leitzmann MF (2006) Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 17:145–156PubMedCrossRef
6.
Zurück zum Zitat Friedenreich CM, Orenstein MR (2002) Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 132:3456S–3464SPubMed Friedenreich CM, Orenstein MR (2002) Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 132:3456S–3464SPubMed
7.
Zurück zum Zitat Samad AK, Taylor RS, Marshall T, Chapman MA (2005) A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis 7:204–213PubMedCrossRef Samad AK, Taylor RS, Marshall T, Chapman MA (2005) A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis 7:204–213PubMedCrossRef
8.
Zurück zum Zitat Huxley R (2007) The role of lifestyle risk factors on mortality from colorectal cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev 8:191–198PubMed Huxley R (2007) The role of lifestyle risk factors on mortality from colorectal cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev 8:191–198PubMed
9.
Zurück zum Zitat Reeves GK, Pirie K, Beral V et al (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335:1134PubMedCrossRef Reeves GK, Pirie K, Beral V et al (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335:1134PubMedCrossRef
10.
Zurück zum Zitat Pischon T, Lahmann PH, Boeing H et al (2006) Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98:920–931PubMed Pischon T, Lahmann PH, Boeing H et al (2006) Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98:920–931PubMed
11.
Zurück zum Zitat Moore LL, Bradlee ML, Singer MR et al (2004) BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord 28:559–567PubMedCrossRef Moore LL, Bradlee ML, Singer MR et al (2004) BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord 28:559–567PubMedCrossRef
12.
Zurück zum Zitat Lee IM, Paffenbarger RS Jr (1992) Quetelet’s index and risk of colon cancer in college alumni. J Natl Cancer Inst 84:1326–1331PubMedCrossRef Lee IM, Paffenbarger RS Jr (1992) Quetelet’s index and risk of colon cancer in college alumni. J Natl Cancer Inst 84:1326–1331PubMedCrossRef
13.
14.
Zurück zum Zitat Bingham SA, Day NE, Luben R et al (2003) Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361:1496–1501PubMedCrossRef Bingham SA, Day NE, Luben R et al (2003) Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361:1496–1501PubMedCrossRef
15.
Zurück zum Zitat Bingham S (2006) The fibre-folate debate in colo-rectal cancer. Proc Nutr Soc 65:19–23PubMed Bingham S (2006) The fibre-folate debate in colo-rectal cancer. Proc Nutr Soc 65:19–23PubMed
16.
Zurück zum Zitat Schatzkin A, Mouw T, Park Y et al (2007) Dietary fiber and whole-grain consumption in relation to colorectal cancer in the NIH-AARP Diet and Health Study. Am J Clin Nutr 85:1353–1360PubMed Schatzkin A, Mouw T, Park Y et al (2007) Dietary fiber and whole-grain consumption in relation to colorectal cancer in the NIH-AARP Diet and Health Study. Am J Clin Nutr 85:1353–1360PubMed
17.
Zurück zum Zitat van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P et al (2009) Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 89:1441–1452CrossRef van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P et al (2009) Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 89:1441–1452CrossRef
18.
Zurück zum Zitat Gonzalez CA, Riboli E (2006) Diet and cancer prevention: where we are, where we are going. Nutr Cancer 56:225–231PubMedCrossRef Gonzalez CA, Riboli E (2006) Diet and cancer prevention: where we are, where we are going. Nutr Cancer 56:225–231PubMedCrossRef
19.
Zurück zum Zitat Wu H, Dai Q, Shrubsole MJ et al (2009) Fruit and vegetable intakes are associated with lower risk of colorectal adenomas. J Nutr 139:340–344PubMed Wu H, Dai Q, Shrubsole MJ et al (2009) Fruit and vegetable intakes are associated with lower risk of colorectal adenomas. J Nutr 139:340–344PubMed
20.
Zurück zum Zitat Willett WC, Stampfer MJ, Colditz GA et al (1990) Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 323:1664–1672PubMed Willett WC, Stampfer MJ, Colditz GA et al (1990) Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 323:1664–1672PubMed
21.
Zurück zum Zitat Alexander DD, Cushing CA, Lowe KA et al (2009) Meta-analysis of animal fat or animal protein intake and colorectal cancer. Am J Clin Nutr 89:1402–1409PubMedCrossRef Alexander DD, Cushing CA, Lowe KA et al (2009) Meta-analysis of animal fat or animal protein intake and colorectal cancer. Am J Clin Nutr 89:1402–1409PubMedCrossRef
22.
Zurück zum Zitat Larsson SC, Wolk A (2006) Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer 119:2657–2664PubMedCrossRef Larsson SC, Wolk A (2006) Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer 119:2657–2664PubMedCrossRef
23.
Zurück zum Zitat Cross AJ, Pollock JR, Bingham SA (2003) Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. Cancer Res 63:2358–2360PubMed Cross AJ, Pollock JR, Bingham SA (2003) Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. Cancer Res 63:2358–2360PubMed
24.
Zurück zum Zitat Sesink AL, Termont DS, Kleibeuker JH, Van der Meer R (1999) Red meat and colon cancer: the cytotoxic and hyperproliferative effects of dietary heme. Cancer Res 59:5704–5709PubMed Sesink AL, Termont DS, Kleibeuker JH, Van der Meer R (1999) Red meat and colon cancer: the cytotoxic and hyperproliferative effects of dietary heme. Cancer Res 59:5704–5709PubMed
25.
Zurück zum Zitat Sanjoaquin MA, Appleby PN, Thorogood M et al (2004) Nutrition, lifestyle and colorectal cancer incidence: a prospective investigation of 10998 vegetarians and non-vegetarians in the United Kingdom. Br J Cancer 90:118–121PubMedCrossRef Sanjoaquin MA, Appleby PN, Thorogood M et al (2004) Nutrition, lifestyle and colorectal cancer incidence: a prospective investigation of 10998 vegetarians and non-vegetarians in the United Kingdom. Br J Cancer 90:118–121PubMedCrossRef
26.
Zurück zum Zitat Norat T, Bingham S, Ferrari P et al (2005) Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 97:906–916PubMedCrossRef Norat T, Bingham S, Ferrari P et al (2005) Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 97:906–916PubMedCrossRef
27.
Zurück zum Zitat Wactawski-Wende J, Kotchen JM, Anderson GL et al (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684–696PubMedCrossRef Wactawski-Wende J, Kotchen JM, Anderson GL et al (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684–696PubMedCrossRef
28.
Zurück zum Zitat Neuhouser ML, Wassertheil-Smoller S, Thomson C et al (2009) Multivitamin use and risk of cancer and cardiovascular disease in the Women’s Health Initiative cohorts. Arch Intern Med 169:294–304PubMedCrossRef Neuhouser ML, Wassertheil-Smoller S, Thomson C et al (2009) Multivitamin use and risk of cancer and cardiovascular disease in the Women’s Health Initiative cohorts. Arch Intern Med 169:294–304PubMedCrossRef
29.
Zurück zum Zitat Malila N, Virtamo J, Virtanen M et al (2002) Dietary and serum alpha-tocopherol, beta-carotene and retinol, and risk for colorectal cancer in male smokers. Eur J Clin Nutr 56:615–621PubMedCrossRef Malila N, Virtamo J, Virtanen M et al (2002) Dietary and serum alpha-tocopherol, beta-carotene and retinol, and risk for colorectal cancer in male smokers. Eur J Clin Nutr 56:615–621PubMedCrossRef
30.
Zurück zum Zitat Giovannucci E (2001) An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 10:725–731PubMed Giovannucci E (2001) An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 10:725–731PubMed
31.
Zurück zum Zitat Botteri E, Iodice S, Raimondi S et al (2008) Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology 134:388–395PubMedCrossRef Botteri E, Iodice S, Raimondi S et al (2008) Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology 134:388–395PubMedCrossRef
32.
Zurück zum Zitat Botteri E, Iodice S, Bagnardi V et al (2008) Smoking and colorectal cancer: a meta-analysis. JAMA 300:2765–2778PubMedCrossRef Botteri E, Iodice S, Bagnardi V et al (2008) Smoking and colorectal cancer: a meta-analysis. JAMA 300:2765–2778PubMedCrossRef
33.
Zurück zum Zitat Paskett ED, Reeves KW, Rohan TE et al (2007) Association between cigarette smoking and colorectal cancer in the women’s health initiative. J Natl Cancer Inst 99:1729–1735PubMedCrossRef Paskett ED, Reeves KW, Rohan TE et al (2007) Association between cigarette smoking and colorectal cancer in the women’s health initiative. J Natl Cancer Inst 99:1729–1735PubMedCrossRef
35.
Zurück zum Zitat Toriola AT, Kurl S, Laukanen JA et al (2008) Alcohol consumption and risk of colorectal cancer: the Findrink study. Eur J Epidemiol 23:395–401PubMedCrossRef Toriola AT, Kurl S, Laukanen JA et al (2008) Alcohol consumption and risk of colorectal cancer: the Findrink study. Eur J Epidemiol 23:395–401PubMedCrossRef
36.
Zurück zum Zitat Bongaerts BW, van den Brandt PA, Goldbohm RA et al (2008) Alcohol consumption, type of alcoholic beverage and risk of colorectal cancer at specific subsites. Int J Cancer 123:2411–2417PubMedCrossRef Bongaerts BW, van den Brandt PA, Goldbohm RA et al (2008) Alcohol consumption, type of alcoholic beverage and risk of colorectal cancer at specific subsites. Int J Cancer 123:2411–2417PubMedCrossRef
37.
Zurück zum Zitat Thygesen LC, Wu K, Gronbaek M et al (2008) Alcohol intake and colorectal cancer: a comparison of approaches for including repeated measures of alcohol consumption. Epidemiology 19:258–264PubMedCrossRef Thygesen LC, Wu K, Gronbaek M et al (2008) Alcohol intake and colorectal cancer: a comparison of approaches for including repeated measures of alcohol consumption. Epidemiology 19:258–264PubMedCrossRef
38.
Zurück zum Zitat Je Y, Liu W, Giovannucci E (2009) Coffee consumption and risk of colorectal cancer: a systematic review and meta-analysis of prospective cohort studies. Int J Cancer 124:1662–1668PubMedCrossRef Je Y, Liu W, Giovannucci E (2009) Coffee consumption and risk of colorectal cancer: a systematic review and meta-analysis of prospective cohort studies. Int J Cancer 124:1662–1668PubMedCrossRef
39.
Zurück zum Zitat Larsson SC, Wolk A (2007) Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 132:1740–1745PubMedCrossRef Larsson SC, Wolk A (2007) Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 132:1740–1745PubMedCrossRef
40.
Zurück zum Zitat Sun CL, Yuan JM, Koh WP, Yu MC (2006) Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 27:1301–1309PubMedCrossRef Sun CL, Yuan JM, Koh WP, Yu MC (2006) Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 27:1301–1309PubMedCrossRef
41.
Zurück zum Zitat Sun CL, Yuan JM, Koh WP et al (2007) Green tea and black tea consumption in relation to colorectal cancer risk: the Singapore Chinese Health Study. Carcinogenesis 28:2143–2148PubMedCrossRef Sun CL, Yuan JM, Koh WP et al (2007) Green tea and black tea consumption in relation to colorectal cancer risk: the Singapore Chinese Health Study. Carcinogenesis 28:2143–2148PubMedCrossRef
42.
Zurück zum Zitat Ransohoff DF (2002) Lessons from the UK sigmoidoscopy screening trial. Lancet 359:1266–1267PubMedCrossRef Ransohoff DF (2002) Lessons from the UK sigmoidoscopy screening trial. Lancet 359:1266–1267PubMedCrossRef
43.
Zurück zum Zitat Stryker SJ, Wolff BG, Culp CE et al (1987) Natural history of untreated colonic polyps. Gastroenterology 93:1009–1013PubMed Stryker SJ, Wolff BG, Culp CE et al (1987) Natural history of untreated colonic polyps. Gastroenterology 93:1009–1013PubMed
44.
Zurück zum Zitat Eide TJ (1986) Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer 38:173–176PubMedCrossRef Eide TJ (1986) Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer 38:173–176PubMedCrossRef
45.
Zurück zum Zitat Birkner BR (2003) Evidence-based prevention of colorectal carcinoma. Dtsch Med Wochenschr 128:2598–2603PubMedCrossRef Birkner BR (2003) Evidence-based prevention of colorectal carcinoma. Dtsch Med Wochenschr 128:2598–2603PubMedCrossRef
46.
Zurück zum Zitat Winawer S, Fletcher R, Rex D et al (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 124:544–560PubMedCrossRef Winawer S, Fletcher R, Rex D et al (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 124:544–560PubMedCrossRef
47.
Zurück zum Zitat Hewitson P, Glasziou P, Watson E et al (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103:1541–1549PubMedCrossRef Hewitson P, Glasziou P, Watson E et al (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103:1541–1549PubMedCrossRef
48.
Zurück zum Zitat Graser A, Stieber P, Nagel D et al (2009) Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 58:241–248PubMedCrossRef Graser A, Stieber P, Nagel D et al (2009) Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut 58:241–248PubMedCrossRef
49.
Zurück zum Zitat Guittet L, Bouvier V, Mariotte N et al (2009) Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 100:1230–1235PubMedCrossRef Guittet L, Bouvier V, Mariotte N et al (2009) Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 100:1230–1235PubMedCrossRef
50.
Zurück zum Zitat Imperiale TF, Ransohoff DF, Itzkowitz SH et al (2004) Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351:2704–2714PubMedCrossRef Imperiale TF, Ransohoff DF, Itzkowitz SH et al (2004) Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351:2704–2714PubMedCrossRef
51.
Zurück zum Zitat Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981PubMedCrossRef Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981PubMedCrossRef
52.
Zurück zum Zitat Muller AD, Sonnenberg A (1995) Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 123:904–910PubMed Muller AD, Sonnenberg A (1995) Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 123:904–910PubMed
53.
Zurück zum Zitat Newcomb PA, Norfleet RG, Storer BE et al (1992) Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84:1572–1575PubMedCrossRef Newcomb PA, Norfleet RG, Storer BE et al (1992) Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84:1572–1575PubMedCrossRef
54.
Zurück zum Zitat Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS (1992) A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326:653–657PubMedCrossRef Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS (1992) A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326:653–657PubMedCrossRef
55.
Zurück zum Zitat Hoff G, Grotmol T, Skovlund E, Bretthauer M (2009) Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 338:b1846PubMedCrossRef Hoff G, Grotmol T, Skovlund E, Bretthauer M (2009) Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 338:b1846PubMedCrossRef
56.
Zurück zum Zitat Lieberman DA, Weiss DG, Bond JH et al (2000) Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 343:162–168PubMedCrossRef Lieberman DA, Weiss DG, Bond JH et al (2000) Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 343:162–168PubMedCrossRef
57.
Zurück zum Zitat Rex DK, Cutler CS, Lemmel GT et al (1997) Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 112:24–28PubMedCrossRef Rex DK, Cutler CS, Lemmel GT et al (1997) Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 112:24–28PubMedCrossRef
58.
Zurück zum Zitat Regula J, Rupinski M, Kraszewska E et al (2006) Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 355:1863–1872PubMedCrossRef Regula J, Rupinski M, Kraszewska E et al (2006) Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 355:1863–1872PubMedCrossRef
59.
Zurück zum Zitat Huppe D, Hartmann H, Felten G et al (2008) Effectiveness of screening colonoscopy in a community-based study. Z Gastroenterol 46:193–200PubMedCrossRef Huppe D, Hartmann H, Felten G et al (2008) Effectiveness of screening colonoscopy in a community-based study. Z Gastroenterol 46:193–200PubMedCrossRef
60.
Zurück zum Zitat Frazier AL, Colditz GA, Fuchs CS, Kuntz KM (2000) Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284:1954–1961PubMedCrossRef Frazier AL, Colditz GA, Fuchs CS, Kuntz KM (2000) Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284:1954–1961PubMedCrossRef
61.
Zurück zum Zitat Brenner H (2008) Efficacy, effectiveness and cost-effectiveness of endoscopic screening methods. Z Gastroenterol 46(Suppl 1):S20–S22PubMedCrossRef Brenner H (2008) Efficacy, effectiveness and cost-effectiveness of endoscopic screening methods. Z Gastroenterol 46(Suppl 1):S20–S22PubMedCrossRef
62.
Zurück zum Zitat van Rijn JC, Reitsma JB, Stoker J et al (2006) Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 101:343–350CrossRef van Rijn JC, Reitsma JB, Stoker J et al (2006) Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 101:343–350CrossRef
63.
Zurück zum Zitat Barclay RL, Vicari JJ, Doughty AS et al (2006) Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 355:2533–2541PubMedCrossRef Barclay RL, Vicari JJ, Doughty AS et al (2006) Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 355:2533–2541PubMedCrossRef
64.
Zurück zum Zitat Schoen RE, Pinsky PF, Weissfeld JL et al (2003) Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA 290:41–48PubMedCrossRef Schoen RE, Pinsky PF, Weissfeld JL et al (2003) Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA 290:41–48PubMedCrossRef
65.
Zurück zum Zitat Singh H, Turner D, Xue L et al (2006) Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 295:2366–2373PubMedCrossRef Singh H, Turner D, Xue L et al (2006) Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 295:2366–2373PubMedCrossRef
66.
Zurück zum Zitat Imperiale TF, Glowinski EA, Lin-Cooper C et al (2008) Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 359:1218–1224PubMedCrossRef Imperiale TF, Glowinski EA, Lin-Cooper C et al (2008) Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 359:1218–1224PubMedCrossRef
67.
Zurück zum Zitat Brenner H, Chang-Claude J, Seiler CM et al (2006) Does a negative screening colonoscopy ever need to be repeated? Gut 55:1145–1150PubMedCrossRef Brenner H, Chang-Claude J, Seiler CM et al (2006) Does a negative screening colonoscopy ever need to be repeated? Gut 55:1145–1150PubMedCrossRef
68.
Zurück zum Zitat Schmiegel W, Pox C, Adler G et al (2005) S3-guideline conference „Colorectal Cancer“ 2004. Dtsch Med Wochenschr 130(Suppl 1):S5–S53PubMedCrossRef Schmiegel W, Pox C, Adler G et al (2005) S3-guideline conference „Colorectal Cancer“ 2004. Dtsch Med Wochenschr 130(Suppl 1):S5–S53PubMedCrossRef
69.
Zurück zum Zitat Pickhardt PJ, Choi JR, Hwang I et al (2003) Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 349:2191–2200PubMedCrossRef Pickhardt PJ, Choi JR, Hwang I et al (2003) Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 349:2191–2200PubMedCrossRef
70.
Zurück zum Zitat Johnson CD, Chen MH, Toledano AY et al (2008) Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 359:1207–1217PubMedCrossRef Johnson CD, Chen MH, Toledano AY et al (2008) Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 359:1207–1217PubMedCrossRef
71.
Zurück zum Zitat Kim DH, Pickhardt PJ, Taylor AJ et al (2007) CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med 357:1403–1412PubMedCrossRef Kim DH, Pickhardt PJ, Taylor AJ et al (2007) CT colonography versus colonoscopy for the detection of advanced neoplasia. N Engl J Med 357:1403–1412PubMedCrossRef
72.
Zurück zum Zitat Ajaj W, Ruehm SG, Gerken G, Goyen M (2006) Strengths and weaknesses of dark-lumen MR colonography: clinical relevance of polyps smaller than 5 mm in diameter at the moment of their detection. J Magn Reson Imaging 24:1088–1094PubMedCrossRef Ajaj W, Ruehm SG, Gerken G, Goyen M (2006) Strengths and weaknesses of dark-lumen MR colonography: clinical relevance of polyps smaller than 5 mm in diameter at the moment of their detection. J Magn Reson Imaging 24:1088–1094PubMedCrossRef
73.
Zurück zum Zitat Kerker J, Albes G, Roer N et al (2008) MR-colonography in hospitalized patients: feasibility and sensitivity. Z Gastroenterol 46:339–343PubMedCrossRef Kerker J, Albes G, Roer N et al (2008) MR-colonography in hospitalized patients: feasibility and sensitivity. Z Gastroenterol 46:339–343PubMedCrossRef
74.
Zurück zum Zitat Weishaupt D, Patak MA, Froehlich J et al (1999) Faecal tagging to avoid colonic cleansing before MRI colonography. Lancet 354:835–836PubMed Weishaupt D, Patak MA, Froehlich J et al (1999) Faecal tagging to avoid colonic cleansing before MRI colonography. Lancet 354:835–836PubMed
75.
Zurück zum Zitat Van Gossum A, Navas MM, Fernandez-Urien I et al (2009) Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 361:264–270CrossRef Van Gossum A, Navas MM, Fernandez-Urien I et al (2009) Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 361:264–270CrossRef
76.
Zurück zum Zitat Eberhart CE, Coffey RJ, Radhika A et al (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188PubMed Eberhart CE, Coffey RJ, Radhika A et al (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188PubMed
77.
Zurück zum Zitat Oshima M, Dinchuk JE, Kargman SL et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809PubMedCrossRef Oshima M, Dinchuk JE, Kargman SL et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809PubMedCrossRef
78.
Zurück zum Zitat Mann JR, Backlund MG, DuBois RN (2005) Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2:202–210PubMedCrossRef Mann JR, Backlund MG, DuBois RN (2005) Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2:202–210PubMedCrossRef
79.
Zurück zum Zitat Giovannucci E, Egan KM, Hunter DJ et al (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609–614PubMedCrossRef Giovannucci E, Egan KM, Hunter DJ et al (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609–614PubMedCrossRef
80.
Zurück zum Zitat Giovannucci E, Rimm EB, Stampfer MJ et al (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241–246PubMed Giovannucci E, Rimm EB, Stampfer MJ et al (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241–246PubMed
81.
Zurück zum Zitat Chan AT, Giovannucci EL, Meyerhardt JA et al (2008) Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134:21–28PubMedCrossRef Chan AT, Giovannucci EL, Meyerhardt JA et al (2008) Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134:21–28PubMedCrossRef
82.
Zurück zum Zitat Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603–1613PubMedCrossRef Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603–1613PubMedCrossRef
83.
Zurück zum Zitat Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55PubMedCrossRef Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55PubMedCrossRef
84.
Zurück zum Zitat Schernhammer ES, Kang JH, Chan AT et al (2004) A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96:22–28PubMedCrossRef Schernhammer ES, Kang JH, Chan AT et al (2004) A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96:22–28PubMedCrossRef
85.
Zurück zum Zitat Burn J, Bishop DT, Mecklin JP et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567–2578PubMedCrossRef Burn J, Bishop DT, Mecklin JP et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567–2578PubMedCrossRef
86.
Zurück zum Zitat Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131–2142PubMedCrossRef Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131–2142PubMedCrossRef
87.
Zurück zum Zitat Dube C, Rostom A, Lewin G et al (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146:365–375PubMed Dube C, Rostom A, Lewin G et al (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146:365–375PubMed
88.
Zurück zum Zitat Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899PubMedCrossRef Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899PubMedCrossRef
89.
Zurück zum Zitat Sandler RS, Halabi S, Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890PubMedCrossRef Sandler RS, Halabi S, Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890PubMedCrossRef
90.
Zurück zum Zitat Benamouzig R, Deyra J, Martin A et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125:328–336PubMedCrossRef Benamouzig R, Deyra J, Martin A et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125:328–336PubMedCrossRef
91.
Zurück zum Zitat Logan RF, Grainge MJ, Shepherd VC et al (2008) Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134:29–38PubMedCrossRef Logan RF, Grainge MJ, Shepherd VC et al (2008) Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134:29–38PubMedCrossRef
92.
Zurück zum Zitat Cole BF, Logan RF, Halabi S et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256–266PubMedCrossRef Cole BF, Logan RF, Halabi S et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256–266PubMedCrossRef
93.
Zurück zum Zitat Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873–884PubMedCrossRef Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873–884PubMedCrossRef
94.
Zurück zum Zitat Solomon SD, McMurray JJV, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080PubMedCrossRef Solomon SD, McMurray JJV, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080PubMedCrossRef
95.
Zurück zum Zitat Arber N, Eagle CJ, Spicak J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885–895PubMedCrossRef Arber N, Eagle CJ, Spicak J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885–895PubMedCrossRef
96.
Zurück zum Zitat Arber N (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev 17:1852–1857PubMedCrossRef Arber N (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev 17:1852–1857PubMedCrossRef
97.
Zurück zum Zitat Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952PubMedCrossRef Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952PubMedCrossRef
98.
Zurück zum Zitat Ju J, Hong J, Zhou JN et al (2005) Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (−)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 65:10623–10631PubMedCrossRef Ju J, Hong J, Zhou JN et al (2005) Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (−)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 65:10623–10631PubMedCrossRef
99.
Zurück zum Zitat Shimizu M, Fukutomi Y, Ninomiya M et al (2008) Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev 17:3020–3025PubMedCrossRef Shimizu M, Fukutomi Y, Ninomiya M et al (2008) Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev 17:3020–3025PubMedCrossRef
100.
Zurück zum Zitat Cho E, Smith-Warner SA, Spiegelman D et al (2004) Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 96:1015–1022PubMedCrossRef Cho E, Smith-Warner SA, Spiegelman D et al (2004) Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 96:1015–1022PubMedCrossRef
101.
Zurück zum Zitat Bonithon-Kopp C, Kronborg O, Giacosa A et al (2000) Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 356:1300–1306PubMedCrossRef Bonithon-Kopp C, Kronborg O, Giacosa A et al (2000) Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 356:1300–1306PubMedCrossRef
102.
Zurück zum Zitat Weingarten MA, Zalmanovici A, Yaphe J (2004) Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev CD003548 Weingarten MA, Zalmanovici A, Yaphe J (2004) Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev CD003548
103.
Zurück zum Zitat Jacobs ET, Jiang R, Alberts DS et al (2004) Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 96:1669–1675PubMedCrossRef Jacobs ET, Jiang R, Alberts DS et al (2004) Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 96:1669–1675PubMedCrossRef
104.
Zurück zum Zitat Early DS, Hill K, Burk R, Palmer I (2002) Selenoprotein levels in patients with colorectal adenomas and cancer. Am J Gastroenterol 97:745–748PubMedCrossRef Early DS, Hill K, Burk R, Palmer I (2002) Selenoprotein levels in patients with colorectal adenomas and cancer. Am J Gastroenterol 97:745–748PubMedCrossRef
105.
Zurück zum Zitat Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963PubMedCrossRef Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963PubMedCrossRef
106.
Zurück zum Zitat Reid ME, Duffield-Lillico AJ, Sunga A et al (2006) Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int J Cancer 118:1777–1781PubMedCrossRef Reid ME, Duffield-Lillico AJ, Sunga A et al (2006) Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int J Cancer 118:1777–1781PubMedCrossRef
107.
Zurück zum Zitat Kim YI, Salomon RN, Graeme-Cook F et al (1996) Dietary folate protects against the development of macroscopic colonic neoplasia in a dose responsive manner in rats. Gut 39:732–740PubMedCrossRef Kim YI, Salomon RN, Graeme-Cook F et al (1996) Dietary folate protects against the development of macroscopic colonic neoplasia in a dose responsive manner in rats. Gut 39:732–740PubMedCrossRef
108.
Zurück zum Zitat Giovannucci E (2002) Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 132:2350S–2355SPubMed Giovannucci E (2002) Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 132:2350S–2355SPubMed
109.
Zurück zum Zitat Jaszewski R, Misra S, Tobi M et al (2008) Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. World J Gastroenterol 14:4492–4498PubMedCrossRef Jaszewski R, Misra S, Tobi M et al (2008) Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. World J Gastroenterol 14:4492–4498PubMedCrossRef
110.
Zurück zum Zitat Cole BF, Baron JA, Sandler RS et al (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351–2359PubMedCrossRef Cole BF, Baron JA, Sandler RS et al (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297:2351–2359PubMedCrossRef
111.
Zurück zum Zitat Figueiredo JC, Levine AJ, Grau MV et al (2008) Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels. Cancer Epidemiol Biomarkers Prev 17:2625–2631PubMedCrossRef Figueiredo JC, Levine AJ, Grau MV et al (2008) Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels. Cancer Epidemiol Biomarkers Prev 17:2625–2631PubMedCrossRef
112.
Zurück zum Zitat Kodach LL, Bleuming SA, Peppelenbosch MP et al (2007) The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 133:1272–1281PubMedCrossRef Kodach LL, Bleuming SA, Peppelenbosch MP et al (2007) The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 133:1272–1281PubMedCrossRef
113.
Zurück zum Zitat Poynter JN, Gruber SB, Higgins PD et al (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184–2192PubMedCrossRef Poynter JN, Gruber SB, Higgins PD et al (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184–2192PubMedCrossRef
114.
Zurück zum Zitat Bonovas S, Filioussi K, Flordellis CS, Sitaras NM (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462–3468PubMedCrossRef Bonovas S, Filioussi K, Flordellis CS, Sitaras NM (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462–3468PubMedCrossRef
Metadaten
Titel
Primäre und sekundäre Prävention sporadischer kolorektaler Karzinome
verfasst von
P. Thermann
Prof. Dr. T. Seufferlein
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 12/2009
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-009-1720-2

Weitere Artikel der Ausgabe 12/2009

Die Onkologie 12/2009 Zur Ausgabe

CME Weiterbildung · Zertifizierte Fortbildung

Moderne molekulare Onkodiagnostik aus methodischer Sicht

In der Diskussion: Komplementäre Onkologie

Komplementäre Therapieverfahren in der Onkologie

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.